

Ready to start planning your care? Call us at [800-525-2225](tel:800-525-2225) to make an appointment.

×



Memorial Sloan Kettering
Cancer Center

[Make an Appointment](#)

[Back](#)

[Find a Physician](#)
[Learn About Cancer & Treatment](#)

ABOUT US

[Our mission, vision & core values](#)

[Leadership](#)

[History](#)

[Inclusion & belonging](#)

[Annual report](#)

[Give to MSK](#)

FOR THE MEDIA



Michael A. Postow, MD

[Melanoma Medical Oncologist](#) ([#about-me](#))



Areas of Expertise

Conditions I Treat

- Melanoma

My Specialties

- Clinical trials

- Immunotherapy
- Targeted therapy

 [Dr. Postow's Office Information \(#contact-and-location\)](#)



Languages: English

Request an Appointment

Our Care Advisors can answer many of your questions. They will connect you with the best healthcare provider for your needs.

[Call 646-497-9067](#)

[Make an appointment](#)

Get to Know Me

I am the Chief of the Melanoma Service at Memorial Sloan Kettering Cancer Center (MSK), where my practice is devoted solely to the care of people with [melanoma](#) . It is my privilege to lead an outstanding group of medical oncologists, nurses, and researchers with world-leading expertise in the treatment and management of melanoma.

Many FDA-approved therapies for patients with melanoma were developed by our team, including the combination of nivolumab (Opdivo®) and ipilimumab (Yervoy®). The regimen has since been recognized as a major scientific advance in melanoma by The American Society of Clinical Oncology.

What I Do at MSK

I'm a melanoma medical oncologist, which is a cancer doctor who specializes in melanoma. This includes superficial spreading, nodular, lentigo maligna, and acral lentiginous melanomas. It also includes eye, mucosal, and rare skin melanomas.

- Chief, Melanoma Service
- Co-Director, Melanoma Disease Management Team

Areas of Expertise

Conditions I Treat

- Melanoma

My Specialties

- Clinical trials
- Immunotherapy
- Targeted therapy

Education & Honors

Education

- MD, New York University School of Medicine

Residencies

- Internal Medicine - Harvard University/Brigham and Women's Hospital

Fellowships

- Medical Oncology - Memorial Sloan Kettering Cancer Center
- Medical Oncology - Weill Cornell Medical College

Board Certifications

- Internal Medicine
- Medical Oncology

Awards and Honors

- Solid Tumor Teacher of the Year Award, Memorial Sloan Kettering Cancer Center (2022, 2019)
- Best Teaching Service Award (Melanoma, 2022)
- 40 Under 40 in Cancer Award, The Lynx Group (2020)
- Julia Zelmanovich Young Alumni Award, New York University Grossman School of Medicine

Insurance Information

Understanding your insurance options is an important part of managing your cancer care. We have relationships with many common healthcare providers and plans.

Don't see your carrier or plan? [We can help you understand your coverage](#) .

If you don't have health insurance or are worried that your care may not be fully covered, our [financial assistance](#) programs may be able to help.

If you have questions about insurance, call us at [646-497-9176](tel:646-497-9176) .

Make an Appointment

New Patients

Scheduling an appointment is easy. Click or call [646-497-9067](tel:646-497-9067) — we're available 24 hours a day, 7 days a week

[Make an Appointment](#)

Current Patients

Request an appointment by calling your Care Team or messaging them in [MSK MyChart](#).

Contact and Location


Office Phone

 [646-888-4589](tel:646-888-4589)

Location

 New York, NY

[Rockefeller Outpatient Pavilion](#)

 160 East 53rd Street
New York, NY 10022

[Get Directions](#)

Looking to see a doctor at a different location? [See all MSK locations](#) .

Colleagues

Doctors at Memorial Sloan Kettering work as teams, with specialists from all different areas. This allows us to consider all your needs together, and to give you the best possible care.

[See all Melanoma Service doctors](https://www.mskcc.org/doctor#:f:Departments=[Medicine,Division%20of%20Solid%20Tumor%20Oncology,Melanoma%20Service]) ([https://www.mskcc.org/doctor#:f:Departments=\[Medicine,Division of Solid Tumor Oncology,Melanoma Service\]](https://www.mskcc.org/doctor#:f:Departments=[Medicine,Division%20of%20Solid%20Tumor%20Oncology,Melanoma%20Service]))

Clinical Trials

- Clinical Trials Co-Investigated by Dr. Postow
- [A Phase 1 Study of PF-07799544 Plus PF-07799933 in People With BRAF V600-Mutated Advanced Melanoma](#)
- [A Phase 2 Study of Fianlimab, Cemiplimab, and Ipilimumab in People With Advanced Melanoma](#)
- [A Phase 2 Study of Patritumab Deruxtecan \(HER3-DXd\) in People With Advanced Melanoma](#)
- [A Phase I/IIA Study of LNS8801 with and without Pembrolizumab Immunotherapy in People with Advanced Melanoma](#)



Find a Clinical Trial for You

Memorial Sloan Kettering's doctors and scientists are constantly developing new treatments for cancer. MSK is typically running hundreds of clinical trials at a given time.

You may be able to participate in a clinical trial even if you are new to MSK. Search our online directory to find trial information and see more about who can participate.

[Search clinical trials](https://www.mskcc.org/cancer-care/clinical-trials) (<https://www.mskcc.org/cancer-care/clinical-trials>)

Research and Publications

Postow MA, Goldman DA, Shoushtari AN, Betof Warner A, Callahan MK, Momtaz P, Smithy JW, Naito E, Cugliari MK, Raber V, Eton O, Nair SG, Panageas KS, Wolchok JD, Chapman PB. Adaptive Dosing of Nivolumab + Ipilimumab Immunotherapy Based Upon Early, Interim Radiographic Assessment in Advanced Melanoma (The ADAPT-IT Study). *J Clin Oncol*. 2022 Apr 1;40(10):1059-1067. doi: 10.1200/JCO.21.01570. Epub 2021 Dec 20. PMID: 34928709; PMCID: PMC8966970.

Postow MA, Knox SJ, Goldman DA, Elhanati Y, Mavinkurve V, Wong P, Halpenny D, Reddy SK, Vado K, McCabe D, Ramirez KA, Macri M, Schwarzenberger P, Ricciardi T, Ryan A, Venhaus R, Momtaz P, Shoushtari AN, Callahan MK, Chapman PB, Wolchok JD, Subrahmanyam PB, Maecker HT, Panageas KS, Barker CA. A Prospective, Phase 1 Trial of Nivolumab, Ipilimumab, and Radiotherapy in Patients with Advanced Melanoma. *Clin Cancer Res*. 2020 Jul 1;26(13):3193-3201. doi: 10.1158/1078-0432.CCR-19-3936. Epub 2020 Mar 23. PMID: 32205463; PMCID: PMC7959513.

Postow MA, Sidlow R, Hellmann MD. Immune-Related Adverse Events Associated with Immune Checkpoint Blockade. *N Engl J Med*. 2018 Jan 11;378(2):158-168. doi: 10.1056/NEJMra1703481. PMID: 29320654.

Postow MA, Chesney J, Pavlick AC, Robert C, Grossmann K, McDermott D, Linette GP, Meyer N, Giguere JK, Agarwala SS, Shaheen M, Ernstoff MS, Minor D, Salama AK, Taylor M, Ott PA, Rollin LM, Horak C, Gagnier P, Wolchok JD, Hodi FS. [Nivolumab and ipilimumab versus ipilimumab in untreated melanoma](#). *N Engl J Med*. 2015 May 21;372(21):2006-17. doi: 10. PMID: 25891304

Pocket Oncology. Drilon AE, Postow MA eds. Philadelphia: Lippincott Williams & Wilkins; 2014.

Publications on PubMed

Visit PubMed for a full listing of Dr. Postow's journal articles. Pubmed is an online index of research papers and other articles from the US National Library of Medicine and the National Institutes of Health.

[See all on PubMed \(http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&db=pubmed&term=Michael%20Postow\)](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&db=pubmed&term=Michael%20Postow)

Disclosures

Members of the MSK Community often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community. These activities outside of MSK further our mission, provide productive collaborations, and promote the practical

application of scientific discoveries.

MSK requires doctors, faculty members, and leaders to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public. Not all disclosed interests and relationships present conflicts of interest. MSK reviews all disclosed interests and relationships to assess whether a conflict of interest exists and whether formal COI management is needed.

Michael A. Postow discloses the following relationships and financial interests:

- Aptitude Health
Professional Services and Activities
- Bristol-Myers Squibb
Professional Services and Activities
- IDEOlogy Health, LLC
Professional Services and Activities
- Lyvgen Biopharma Holdings Ltd.
Professional Services and Activities

- Merck & Co Inc.
Professional Services and Activities
- MJH Associates
Professional Services and Activities
- Pfizer, Inc.
Professional Services and Activities
- UptoDate
Intellectual Property Rights

If you're a patient at MSK and would like more information about your doctor's external relationships, please talk with your doctor.

The information published here is a complement to other publicly reported data and is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.

This page and data include information for a specific MSK annual disclosure period (January 1, 2024 through disclosure submission in spring 2025). This data reflects interests that may or may not

still exist. This data is updated annually.

Learn more about MSK's COI policies [here](#) . For questions regarding MSK's COI-related policies and procedures, email MSK's Compliance Office at ecoi@mskcc.org .

[View all disclosures \(https://www.mskcc.org/disclosures\)](https://www.mskcc.org/disclosures)

© 2026 Memorial Sloan Kettering Cancer Center